Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

2005520 citationsJournal Article

Authors

Thomas E. Witzig · Mayo Clinic

Susan M. Geyer · Mayo Clinic in Arizona

Irene M. Ghobrial · Mayo Clinic in Arizona

David J. Inwards · Mayo Clinic in Arizona

Rafaël Fonseca · Mayo Clinic

Paul J. Kurtin · Mayo Clinic in Arizona

Stephen M. Ansell ·

Abstract

Single-agent temsirolimus has substantial antitumor activity in relapsed MCL. This study demonstrates that agents that selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit. Further studies of this agent in MCL and other lymphoid malignancies are warranted.

Topics & Keywords

Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 23, pp. 5347-5356

DOI: 10.1200/jco.2005.13.466

Field-Weighted Citation Impact: 24.59